The Food and Drug Administration (FDA) has recently approved Guardant Health’s Shield blood test, marking it as a primary screening tool for colorectal cancer for average-risk adults aged 45 and older. This approval positions the Shield test as a more appealing and convenient alternative to traditional colorectal cancer screening methods, such as colonoscopies and stool-based tests, potentially leading to higher screening participation.
Guardant Health suggests that the ease of obtaining a blood sample during a routine doctor’s visit with the Shield test could cater to those reluctant or unable to undergo a colonoscopy or manage a stool test. The test functions by detecting alterations in cell-free DNA associated with colorectal cancer, aiming to simplify and encourage regular screening.
Despite its approval, some concerns remain about the test’s sensitivity, particularly in the early stages of colorectal cancer and its ability to detect advanced adenomas—a precursor to colorectal cancer. During the FDA advisory committee review held in May, the Shield test was endorsed with a vote of 7-2, on the grounds that the benefits of increased screening outweighed potential risks. However, panelists expressed apprehension regarding the test’s ability to detect early disease and advanced adenomas, fearing that false negative results could prevent timely and necessary follow-up tests.
In a detailed report, the Shield test demonstrated a sensitivity of 83.1% in detecting colorectal cancer but only 13.2% in identifying advanced adenomas. This discrepancy highlights a critical gap in the test’s ability to catch these high-risk growths, which are significant in the early prevention of colorectal cancer.
Despite these concerns, market analysts foresee a continued demand for the test, driven by both its convenience and the massive unscreened population. The colorectal screening market, valued at approximately $20 billion by Leerink Partners, still anticipates colonoscopy to remain the primary method of screening due to its comprehensive diagnostic advantage, followed by alternative tests like Exact Sciences’ Cologuard stool test.
The FDA’s approval requires that the Shield test’s labeling includes precautionary language regarding its limited sensitivity in detecting advanced adenomas and Stage 1 cancer. Dan Brennan from TD Cowen mentioned this labeling explicitly, indicating regulators’ caution despite the test’s approval.
Leerink Partners suggests that Shield is strategically placed to target over 50 million individuals who currently do not participate in colorectal cancer screening. The urgency of improving screening rates is underscored by data showing that a significant number of colorectal cancer deaths occur among individuals not up-to-date with their screening. The convenience of a blood test like Shield could potentially address these gaps by providing an easier, less invasive screening option.
According to Daniel Chung, a Harvard Medical School gastroenterologist, the approval of Shield presents a significant advancement in cancer detection efforts. Chung emphasized the potential of increased screening rates, facilitated by the simplicity and accessibility of the blood test, to save more lives through early detection.
In summary, while Guardant Health’s Shield test introduces a promising and user-friendly option in the landscape of colorectal cancer screening, its efficacy in detecting early-stage cancer and advanced adenomas remains a point of concern. Despite these challenges, industry experts, healthcare providers, and companies anticipate that increased adoption and convenience offered by Shield could lead to higher overall screening rates, thus playing a crucial role in combating colorectal cancer mortality.
#Guardant #wins #FDA #approval #colon #cancer #blood #test
